A Phase 1 interventional study of Lobradimil and Amphotericin B in Meningitis, Cryptococcal and HIV Infections, sponsored by Alkermes, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Alkermes, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing Amphotericin B in Meningitis, Cryptococcal — 1 open to participants now, 1 under way, none of them phase 3. Amphotericin B · Meningitis, Cryptococcal.
Among the 15 studies testing Amphotericin B in Meningitis, Cryptococcal, this one is the only one in phase 1, and was the 1st registered.
54 studies on the registry are indexed under Meningitis, Cryptococcal; 6 are open to participants now.
Browse Meningitis, Cryptococcal studies →1 of the 15 studies testing Amphotericin B in Meningitis, Cryptococcal is open now, in 1 country. Recruiting first, the newest first:
Huashan Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Amphotericin B: first FDA approval 1964 (FUNGIZONE). What it is approved for, and how studies give it, is on its page →
Of the 4 Meningitis, Cryptococcal studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 120 across the 9 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 15 have an industry lead sponsor. The 9 most frequent:
Alkermes, Inc. is the lead sponsor of 83 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.
Alkermes, Inc. has 1 study filed under Meningitis, Cryptococcal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing Amphotericin B in Meningitis, Cryptococcal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety of escalating doses of RMP-7 administered in persons with HIV infection and cryptococcal meningitis and to determine the MTD of the drug. To evaluate the pharmacokinetics, including cerebrospinal fluid (CSF) penetration, of amphotericin B when administered with RMP-7.
Patients receive intravenous RMP-7 added to conventional therapy with intravenous amphotericin B (with or without flucytosine). Treatment continues for 14 days, with follow-up visits 4 and 12 weeks later.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Concurrent Medication:
Allowed:
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Patients with the following prior conditions are excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is completed, as verified in Dec 1994. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amphotericin B